Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals
NPPA releases Revised MRP for 543 brands of Anti-Cancer Medicines; List to be updated on continual basis; New Prices Effective from November 9, 2026
Posted On:
28 OCT 2026 6:44PM by PIB Delhi
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has released a list of 543 brands of anti cancer medicines with their revised Maximum Retail Price (MRP). The revised MRPs will be effective from November 9, 2026. The revised price list reflects the information submitted by companies up to October 27, 2026 and it will be updated as and when manufacturers submit their revised prices of non-scheduled anti-cancer drugs.
Some brands of the anti cancer medicines with their pre-revised and revised prices:
|
Company Name
|
Drug Name
|
Strength & Dosage Form
|
Brand Name
|
Pack Size
|
Old MRP (₹)
|
Revised MRP (₹)
|
|
RPG LIFE SCIENCES LTD
|
Anastrozole
|
1 MG Tablet
|
ANARZOLE
|
10 tablets
|
695.76
|
73.00
|
|
Dr. Reddys Laboratories Limited
|
Azacitidine
|
100 MG Injection
|
Azacytin
|
1
|
6,337.00
|
1,495.04
|
|
Abbott Healthcare Pvt. Ltd.
|
Bevacizumab
|
100 mg/4 ml Injection
|
BEVACIZAB
|
4 ml vial
|
21,767.70
|
5,930.13
|
|
NATCO PHARMA LIMITED
|
Dasatinib
|
20 MG Tablet
|
Dasanat 20
|
60 tablets
|
2,812.50
|
1,085.93
|
|
RPG LIFE SCIENCES LTD
|
Denosumab
|
60 MG Injection
|
Debrumab 60 mg
|
1 ml PFS
|
22,031.25
|
5,941.00
|
|
RPG LIFE SCIENCES LTD
|
Enzalutamide
|
40 MG Capsule
|
Enuta
|
28 capsules
|
6,578.20
|
2,232.00
|
|
NEON LABORATORIES LIMITED
|
Erlotinib
|
150 MG Tablet
|
ERLIB
|
1 Plastic Bottle of 30 tablets
|
4,637.45
|
2,008.00
|
|
HETERO HEALTHCARE LTD
|
Fludarabine
|
50 MG Injection
|
FLUDANOX
|
vial
|
14,235.00
|
2,432.00
|
|
RPG LIFE SCIENCES LTD
|
Fulvestrant
|
50 MG Injection
|
Fulbreca
|
5 ml vial
|
26,072.16
|
5,491.00
|
The complete list of 543 brands of Anti-Cancer medicines with revised MRPs is available here. (LINK). The NPPA portal is updated on a continual basis.
On October 17, 2026, NPPA had announced Trade Margin Rationalisation (TMR) of 137 non-scheduled anti-cancer drugs in public interest to address excessive trade margins, make cancer treatment more affordable and improve access to anti-cancer medicines. Manufacturers were instructed to submit their revised list to NPPA.
The 137 non-scheduled anti-cancer drugs include immunotherapy medicines used in the treatment of over 20 types of cancer, Denosumab used by breast and prostate cancer patients, Pegfilgrastim used to prevent neutropenia in cancer patients, and Bevacizumab, which is approved for the treatment of colon, ovarian and cervical cancers.
*****
PC/PM
(Release ID: 2329698)
Visitor Counter : 3694